EuroBiotech: More Articles of Note

> The U.K drugmaker AstraZeneca said it has penned a deal to sell Germany’s Grünenthal rights to its migraine treatment Zomig for all markets outside of Japan. AZ will get $200 million when the deal is done and up to $102 million in additional payments if targets are hit. FiercePharma story

> Novo Nordisk has won EU approval for its new haemophilia drug Reflixia and is planning its first European launches in the fourth quarter. Statement

> Takeda has broken ground on construction of a new €40 million expansion of its production facility in Dublin, Ireland. The high containment production plant will be dedicated to producing Takeda’s blood cancer peptide Ninlaro. Irish Examiner story


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

> Ipsen has appointed Natixis to purchase 160,000 of its shares, or about 0.2% of the share capital, over the next 2 months. The stock will be allocated to cover its free performance share allocation plan. Release

> In a Joint Declaration published this week and co-signed by European biopharma R&D lobby group EFPIA, 23 EU business signatories are calling on the European Commission, the European Parliament and the Council of the European Union to develop an “ambitious” next EU Research & Innovation Framework Programme. Public letter

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.